Sign In
Buy CERT
$8.10
+0.320 (+4.11%)
At Close: Jul 31, 2026
Certara Announces Expansion of Clinical Technology Collaboration with Merck
08:00am, Tuesday, 08'th Jul 2025
RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
09:10am, Saturday, 28'th Jun 2025
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript
07:22pm, Monday, 05'th May 2025
Certara, Inc. (NASDAQ:CERT ) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Offi
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates
06:51pm, Monday, 05'th May 2025
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.10 per share a year ago.
Certara Reports First Quarter 2025 Financial Results
04:15pm, Monday, 05'th May 2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal yea
Certara to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 29'th Apr 2025
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the follow
Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy?
11:05am, Monday, 28'th Apr 2025
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Momentum Stocks That Could Soar Post-Market Volatility
08:02am, Monday, 21'st Apr 2025
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
02:08pm, Monday, 14'th Apr 2025
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
08:15am, Monday, 14'th Apr 2025
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution des
Buy Certara After The FDA Announcement
01:15pm, Friday, 11'th Apr 2025
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, wit
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?
11:05am, Friday, 11'th Apr 2025
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
10:44am, Friday, 11'th Apr 2025
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Certara price target raised by $4 at Baird, here's why
08:15am, Friday, 11'th Apr 2025
21 May
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
08:00am, Tuesday, 01'st Apr 2025
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologic
